- Home
- TVGN vs ADAG Comparison
TVGN vs ADAG Comparison
Compare TVGN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | ADAG |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 90.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TVGN | ADAG |
|---|---|---|
| Price | $0.35 | $2.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 645.7K | 70.9K |
| Earning Date | 11-14-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,204.00 |
| Revenue This Year | N/A | $4,446.34 |
| Revenue Next Year | N/A | $30.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $1.30 |
| 52 Week High | $1.92 | $3.16 |
Technical Indicators
Market Signals| Indicator | TVGN | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 70.67 |
| Support Level | $0.32 | $1.69 |
| Resistance Level | $0.37 | $1.98 |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 48.34 | 74.65 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.